Skip to content

Market/Novel Tech

VeonGen Therapeutics GmbH announce re-branding of the company (previously ViGeneron) and the progression of treatments for Stargardt’s disease and retinitis pigmentosa.

VeonGen Therapeutics GmbH, based in Munich, Germany, have announced the progression of two proprietary gene therapies to the clinic based on a novel gene therapy… Read More »VeonGen Therapeutics GmbH announce re-branding of the company (previously ViGeneron) and the progression of treatments for Stargardt’s disease and retinitis pigmentosa.

Ashvattha Therapeutics has announced positive Phase 2 results for subcutaneous migaldendranib, delivered via a hydroxyl dendrimer for retinal vascular disease.

Ashvattha Therapeutics, based in Redwood City, California, have announced positive interim Phase 2 results for migaldendranib (MGB) and hydroxyl dendrimer, aimed to treat retinal vascular… Read More »Ashvattha Therapeutics has announced positive Phase 2 results for subcutaneous migaldendranib, delivered via a hydroxyl dendrimer for retinal vascular disease.

Opus Genetics Inc., has announced 12-month summary results for OPGx-LCA5 – an experimental gene therapy treatment of LCA5 retinal disease. 

Opus Genetics Inc., (NASDAQ: IRD), based in Raleigh, North Carolina, has announced the one-year summary results from adult patients treated in an ongoing Phase 1/2… Read More »Opus Genetics Inc., has announced 12-month summary results for OPGx-LCA5 – an experimental gene therapy treatment of LCA5 retinal disease. 

LumiThera Inc., obtains FDA authorisation in the US on a photo-biomodulation (PBT) medical device – “Valeda” –  for the treatment of dry AMD. 

LumiThera Inc., based in Seattle, Washington, USA, has recently received the U.S. Food & Drug Administration (FDA) authorisation, marketing for “Valeda Light Delivery System” for… Read More »LumiThera Inc., obtains FDA authorisation in the US on a photo-biomodulation (PBT) medical device – “Valeda” –  for the treatment of dry AMD. 

Atsena Therapeutics has announced the grant of U.S. FDA Fast Track Designation for ATSN-201 gene therapy for the treatment of X-linked retinoschisis. 

Atsena Therapeutics, based in Durham, North Carolina, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ATSN-201, for… Read More »Atsena Therapeutics has announced the grant of U.S. FDA Fast Track Designation for ATSN-201 gene therapy for the treatment of X-linked retinoschisis. 

Opthea Ltd (ASX/NASDAQ: OPT) have announced summary Phase 3 results for OPT-302 (sozinibercept) for wet AMD, following suspending shares at the Australian and NASDAQ exchanges.

Opthea Limited (ASX/NASDAQ: OPT), based in Melbourne, Australia and Princeton, New Jersey, have announced summary results from its global Phase 3 clinical trial “COAST” (Combination… Read More »Opthea Ltd (ASX/NASDAQ: OPT) have announced summary Phase 3 results for OPT-302 (sozinibercept) for wet AMD, following suspending shares at the Australian and NASDAQ exchanges.

Encapsulated cell therapy from Neurotech Pharmaceuticals has reported FDA approval for the treatment for MacTel (Macular Telangiectasia Type 2).

Neurotech Pharmaceutics, Inc., a private clinical stage biotech company based in Cumberland, Rhode Island, US, has announcedthat the Food and Drug Administration (FDA) has approved… Read More »Encapsulated cell therapy from Neurotech Pharmaceuticals has reported FDA approval for the treatment for MacTel (Macular Telangiectasia Type 2).

Final efficacy and safety results for the conclusion of a Phase III trial with LUMEVOQ (GS010; lenadogene nolparvovec) reports visual acuity improvement for ND4-LHON patients.

The outcomes of an experimental treatment of “LUMEVOQ” (GS010; lenadogene nolparvovec), for ND4-LHON patients, were presented this month by GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985,… Read More »Final efficacy and safety results for the conclusion of a Phase III trial with LUMEVOQ (GS010; lenadogene nolparvovec) reports visual acuity improvement for ND4-LHON patients.

Ocugen Inc., receives European Medicines Agency (EMA) designation of Advanced Therapy Medicinal Product (ATMP) for “OCU400” to enter for Phase 3 for retinitis pigmentosa. 

Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced that the European Commission has provided a positive opinion from the European… Read More »Ocugen Inc., receives European Medicines Agency (EMA) designation of Advanced Therapy Medicinal Product (ATMP) for “OCU400” to enter for Phase 3 for retinitis pigmentosa.